ArticleSociology of health & illness2016
Can a pill prevent HIV? Negotiating the biomedicalisation of HIV prevention.
Article in Sociology of health & illness, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Thematic synthesis HIV prevention qualitative studies in men who have sex with men (MSM).Colombia medica (Cali, Colombia) · 2019Pooled it
- Protocol for a systematic search and critical discourse analysis of research on national HIV pre-exposure prophylaxis programmes among gay, bisexual, and other men who have sex with men.HRB open research · 2024Article
- Navigating the Viral Divide: Sexual and Gender Minority Community Perspectives on Treatment as Prevention.AIDS education and prevention : official publication of the International Society for AIDS Education · 2023Article
- "What other choices might I have made?": Sexual Minority Men, the PrEP Cascade and the Shifting Subjective Dimensions of HIV Risk.Qualitative health research · 2022Article
- Ambivalence and the biopolitics of HIV pre-exposure prophylaxis (PrEP) implementation.Social theory & health : STH · 2022Article
- HIV-serodifferent couples' perspectives and practices regarding HIV prevention strategies: A mixed methods study.PLOS global public health · 2022Article
- Moral practices shaping HIV disclosure among young gay and bisexual men living with HIV in the context of biomedical advance.Culture, health & sexuality · 2021Article
- Configuring the PrEP user: framing pre-exposure prophylaxis in UK newsprint 2012-2016.Culture, health & sexuality · 2021Article
- Excitable models: Projections, targets, and the making of futures without disease.Sociology of health & illness · 2021Article
- Article
- The significance and expectations of HIV cure research among people living with HIV in Australia.PloS one · 2020Article
- Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis - a qualitative analysis.Journal of the International AIDS Society · 2019Article
- Access, accountability, and the proliferation of psychological therapy: On the introduction of the IAPT initiative and the transformation of mental healthcare.Social studies of science · 2019Article
- What are the motivations and barriers to pre-exposure prophylaxis (PrEP) use among black men who have sex with men aged 18-45 in London? Results from a qualitative study.Sexually transmitted infections · 2019Article
- Making Meaning of the Impact of Pre-Exposure Prophylaxis (PrEP) on Public Health and Sexual Culture: Narratives of Three Generations of Gay and Bisexual Men.Archives of sexual behavior · 2019Article
- Navigating HIV citizenship: identities, risks and biological citizenship in the treatment as prevention era.Health, risk & society · 2019Article
- "Is it making any difference?" A qualitative study examining the treatment-taking experiences of asymptomatic people living with HIV in the context of Treat-all in Eswatini.Journal of the International AIDS Society · 2019Article
- Imagining Interventions for Collective Sex Environments.Archives of sexual behavior · 2019Article
- Clinical exigencies, psychosocial realities: negotiating HIV pre-exposure prophylaxis beyond the cascade among gay, bisexual and other men who have sex with men in Canada.Journal of the International AIDS Society · 2018Article
- 'WTF is PrEP?': attitudes towards pre-exposure prophylaxis among men who have sex with men and transgender women in New York City.Culture, health & sexuality · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
This article examines how biomedicalisation is encountered, responded to and negotiated within and in relation to new biomedical forms of HIV prevention. We draw on exploratory focus group discussions on pre-exposure prophylaxis (PrEP) and treatment as prevention (TasP) to examine how the processes of biomedicalisation are affected by and affect the diverse experiences of communities who have been epidemiologically framed as 'vulnerable' to HIV and towards whom PrEP and TasP will most likely be targeted. We found that participants were largely critical of the perceived commodification of HIV prevention as seen through PrEP, although this was in tension with the construction of being medical consumers by potential PrEP candidates. We also found how deeply entrenched forms of HIV stigma and homophobia can shape and obfuscate the consumption and management of HIV-related knowledge. Finally, we found that rather than seeing TasP or PrEP as 'liberating' through reduced levels of infectiousness or risk of transmission, social and legal requirements of responsibility in relation to HIV risk reinforced unequal forms of biomedical self-governance. Overall, we found that the stratifying processes of biomedicalisation will have significant implications in how TasP, PrEP and HIV prevention more generally are negotiated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.